Citadel Advisors
BCLI

Citadel Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Citadel Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$1.73K – 14497
2024
Q3 		$1.73K Buy
500
+20
+4% +$94 ﹤0.01% 13818
2024
Q2 		$2.44K Buy
480
+427
+806% +$3.2K ﹤0.01% 13686
2024
Q1 		$452 Sell
53
-120
-69% -$660 ﹤0.01% 14329
2023
Q4 		$710 Sell
173
-5,194
-97% -$15.6K ﹤0.01% 13957
2023
Q3 		$16.1K Sell
5,367
-2,406
-31% -$54.7K ﹤0.01% 12788
2023
Q2 		$240K Sell
7,773
-394
-5% -$16.3K ﹤0.01% 9499
2023
Q1 		$404K Buy
8,167
+6,000
+277% +$174K ﹤0.01% 8750
2022
Q4 		$53.3K Buy
2,167
+1,060
+96% +$39.6K ﹤0.01% 12041
2022
Q3 		$73K Sell
1,107
-186
-14% -$9.33K ﹤0.01% 11342
2022
Q2 		$54K Sell
1,293
-534
-29% -$24K ﹤0.01% 11886
2022
Q1 		$92K Sell
1,827
-1,693
-48% -$83.1K ﹤0.01% 12356
2021
Q4 		$211K Sell
3,520
-520
-13% -$25.6K ﹤0.01% 11738
2021
Q3 		$200K Sell
4,040
-1,993
-33% -$105K ﹤0.01% 11979
2021
Q2 		$344K Sell
6,033
-494
-8% -$26.4K ﹤0.01% 10930
2021
Q1 		$375K Buy
6,527
+1,000
+18% +$75.5K ﹤0.01% 10335
2020
Q4 		$375K Sell
5,527
-80
-1% -$10.9K ﹤0.01% 8677
2020
Q3 		$1.42M Buy
5,607
+2,254
+67% +$462K ﹤0.01% 5369
2020
Q2 		$564K Buy
3,353
+1,866
+125% +$201K ﹤0.01% 6857
2020
Q1 		$103K Buy
+1,487
New +$116K ﹤0.01% 8614
2019
Q3 		– Sell
-1,540
Closed -$91K – 9150
2019
Q2 		$91K Buy
1,540
+87
+6% +$5.07K ﹤0.01% 8564
2019
Q1 		$95K Buy
+1,453
New +$82.7K ﹤0.01% 8576
2018
Q4 		– Sell
-687
Closed -$39K – 9094
2018
Q3 		$39K Buy
+687
New +$41.5K ﹤0.01% 8857

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BCLI Position: Q3 2023 in Review

Citadel Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 2,730 shares — an estimated $62.1K sold.

Citadel Advisors first reported a position in BCLI in Q1 2016 and held it in 17 quarters. The position peaked at $195K in Q2 2021. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Citadel Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 2,730 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $62.1K.
  • Citadel Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2016 and held it in 17 quarters.
  • Citadel Advisors's BRAINSTORM CELL THERAPUTC position peaked at $195K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.